CL2018002287A1 - Derivados de tetrahidroisoquinolina. - Google Patents
Derivados de tetrahidroisoquinolina.Info
- Publication number
- CL2018002287A1 CL2018002287A1 CL2018002287A CL2018002287A CL2018002287A1 CL 2018002287 A1 CL2018002287 A1 CL 2018002287A1 CL 2018002287 A CL2018002287 A CL 2018002287A CL 2018002287 A CL2018002287 A CL 2018002287A CL 2018002287 A1 CL2018002287 A1 CL 2018002287A1
- Authority
- CL
- Chile
- Prior art keywords
- muscle
- disorders
- troponine
- treat
- quick
- Prior art date
Links
- 125000003039 tetrahydroisoquinolinyl group Chemical class C1(NCCC2=CC=CC=C12)* 0.000 title 1
- 210000003205 muscle Anatomy 0.000 abstract 4
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000007469 Actins Human genes 0.000 abstract 1
- 108010085238 Actins Proteins 0.000 abstract 1
- 208000029578 Muscle disease Diseases 0.000 abstract 1
- 208000021642 Muscular disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 208000018360 neuromuscular disease Diseases 0.000 abstract 1
- 210000003903 pelvic floor Anatomy 0.000 abstract 1
- 210000002027 skeletal muscle Anatomy 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
- C12N2509/10—Mechanical dissociation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Child & Adolescent Psychology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
COMPUESTOS NOVEDOSOS DERIVADOS DE TETRAHIDROISOQUINOLINA QUE PUEDEN USARSE COMO UN INGREDIENTE ACTIVO PARA UNA COMPOSICIÓN FARMACÉUTICA, Y EN PARTICULAR, PARA UNA COMPOSICIÓN FARMACÉUTICA ÚTIL PARA PREVENIR O TRATAR UNA ENFERMEDAD O CONDICIÓN QUE RESPONDE A LA MODULACIÓN DE LA CONTRACTILIDAD DEL SARCÓMERO ESQUELÉTICO. ESTO PUEDE LOGRARSE, POR EJEMPLO, POR MODULACIÓN DEL COMPLEJO DE TROPONINA DEL SARCÓMERO DE MÚSCULO ESQUELÉTICO RÁPIDO MEDIANTE UNA O MÁS DE MIOSINA ESQUELÉTICA RÁPIDA, ACTINA, TROPOMIOSINA, TROPONINA C, TROPONINA I, Y TROPONINA T, Y FRAGMENTOS E ISOFORMAS DE LAS MISMAS. LOS COMPUESTOS DERIVADOS DE TETRAHIDROISOQUINOLINA PUEDEN USARSE ENTONCES COMO AGENTE PARA PREVENIR O TRATAR 1) TRASTORNOS NEUROMUSCULARES, 2) TRASTORNOS DE MÚSCULOS VOLUNTARIOS, 3) TRASTORNOS DEL SNC EN LOS CUALES LA DEBILIDAD MUSCULAR, ATROFIA, Y FATIGA SON SÍNTOMAS PROMINENTES, 4) SÍNTOMAS MUSCULARES QUE DERIVAN DE TRASTORNOS SISTÉMICOS, Y 5) DISFUNCIONES DEL PISO PÉLVICO Y DEL MÚSCULO DEL ESFÍNTER URETRAL/ANAL.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662285039P | 2016-02-12 | 2016-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018002287A1 true CL2018002287A1 (es) | 2019-01-04 |
Family
ID=59561239
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018002287A CL2018002287A1 (es) | 2016-02-12 | 2018-08-10 | Derivados de tetrahidroisoquinolina. |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9914741B2 (es) |
| EP (2) | EP3413892B1 (es) |
| JP (2) | JP6832943B2 (es) |
| KR (1) | KR20180120701A (es) |
| CN (2) | CN109069498B (es) |
| AR (1) | AR107592A1 (es) |
| AU (1) | AU2017217663B2 (es) |
| BR (1) | BR112018016475A2 (es) |
| CA (1) | CA3012839A1 (es) |
| CL (1) | CL2018002287A1 (es) |
| CO (1) | CO2018007920A2 (es) |
| CY (1) | CY1125222T1 (es) |
| DK (1) | DK3413892T3 (es) |
| ES (1) | ES2913423T3 (es) |
| HR (1) | HRP20220655T1 (es) |
| HU (1) | HUE058820T2 (es) |
| IL (1) | IL261055B (es) |
| LT (1) | LT3413892T (es) |
| MA (1) | MA44018B1 (es) |
| MD (1) | MD3413892T2 (es) |
| MX (1) | MX379159B (es) |
| NZ (1) | NZ746311A (es) |
| PH (1) | PH12018501694B1 (es) |
| PL (1) | PL3413892T3 (es) |
| PT (1) | PT3413892T (es) |
| RS (1) | RS63240B1 (es) |
| RU (1) | RU2743424C2 (es) |
| SG (1) | SG11201806416XA (es) |
| SI (1) | SI3413892T1 (es) |
| SM (1) | SMT202200201T1 (es) |
| TW (2) | TWI719138B (es) |
| UA (1) | UA124879C2 (es) |
| WO (1) | WO2017139526A1 (es) |
| ZA (1) | ZA201804947B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180120701A (ko) | 2016-02-12 | 2018-11-06 | 아스테라스 세이야쿠 가부시키가이샤 | 테트라히드로이소퀴놀린 유도체 |
| GB201905721D0 (en) | 2019-04-24 | 2019-06-05 | Univ Dundee | Compounds |
| JP2023548342A (ja) | 2020-11-06 | 2023-11-16 | サイトキネティックス， インコーポレイテッド | 二環式１，４－ジアゼパノン及びその治療的使用 |
| WO2025080100A1 (ko) * | 2023-10-11 | 2025-04-17 | 한국화학연구원 | 신규한 디-아미드 화합물, 이의 제조방법, 이를 유효성분으로 포함하는 암 또는 자가면역질환의 예방 또는 치료용 약학적 조성물 |
| CN117379425A (zh) * | 2023-11-14 | 2024-01-12 | 广州日聚商贸发展有限公司 | 喹啉-4-羧酸在抗衰老产品以及保护肝脏、促进肝脏再生产品制备中的应用 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3301857A (en) | 1963-08-26 | 1967-01-31 | Hoffmann La Roche | Spiro |
| SE368009B (es) | 1971-09-16 | 1974-06-17 | Kabi Ab | |
| ATE232863T1 (de) * | 1996-08-06 | 2003-03-15 | Pfizer | Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate |
| CA2263479A1 (en) | 1996-09-25 | 1998-04-02 | Zeneca Limited | Quinoline derivatives inhibiting the effect of growth factors such as vegf |
| US6410254B1 (en) | 1999-05-18 | 2002-06-25 | Cytokinetics | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US7202051B1 (en) | 1999-05-18 | 2007-04-10 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| US6743599B1 (en) | 1999-05-18 | 2004-06-01 | Cytokinetics, Inc. | Compositions and assays utilizing ADP or phosphate for detecting protein modulators |
| DE60024631T2 (de) * | 1999-07-26 | 2006-06-14 | Banyu Pharma Co Ltd | Biaryl-harnstoff-derivate |
| JP2001106673A (ja) * | 1999-07-26 | 2001-04-17 | Banyu Pharmaceut Co Ltd | ビアリールウレア誘導体 |
| GB0321538D0 (en) | 2003-09-13 | 2003-10-15 | Glaxo Group Ltd | Therapeutically useful compounds |
| WO2005105802A1 (en) | 2004-04-28 | 2005-11-10 | Takeda Pharmaceutical Company Limited | Fused quinoline derivative and use thereof |
| BRPI0620151A2 (pt) | 2005-12-22 | 2010-06-29 | Wyeth Corp | composto; composição farmacêutica; método de tratar ou inibir o crescimento de células tumorais cancerosas em um mamìfero que deste necessita; método; e processo |
| GB0613208D0 (en) | 2006-07-03 | 2006-08-09 | Glaxo Group Ltd | Compounds |
| PT2583970E (pt) * | 2006-08-02 | 2016-02-08 | Cytokinetics Inc | Certas entidades químicas, composições e métodos compreendendo imidazopirimidinas |
| BRPI0722064A2 (pt) | 2006-12-27 | 2014-04-01 | Sanofi Aventis | Derivados de isoquinolona substituídos por cicloalquilamina |
| ES2428344T3 (es) | 2007-01-05 | 2013-11-07 | Daiichi Sankyo Company, Limited | Derivado de aminopirrolidina sustituido fusionado |
| CL2008001500A1 (es) | 2007-05-25 | 2008-12-26 | Amgen Inc | Compuestos derivados de hidroxietil amina sustituidas, moduladores de betasecretasa; proceso de preparacion de dichos c ompuestos; composicion farmaceutica que los comprende; y su uso para tratar un trastorno neurologico, tal como alzheimer, sindrome de down, demencia degenerativa, entre otros. |
| JP5451646B2 (ja) * | 2008-02-27 | 2014-03-26 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | １１β−ヒドロキシステロイドデヒドロゲナーゼ１型の阻害剤 |
| CN101518971B (zh) * | 2008-02-29 | 2012-07-18 | E.I.内穆尔杜邦公司 | 聚酯叠层膜和使用该叠层膜的太阳能电池板 |
| RU2498981C2 (ru) * | 2008-10-02 | 2013-11-20 | Тайсо Фармасьютикал Ко., Лтд. | 7-пиперидиноалкил-3,4-дигидрохинолоновые производные, обладающие антагонистическим действием на рецептор мсн (меланин-концентрирующего гормона) |
| KR20110099687A (ko) | 2008-10-29 | 2011-09-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체 |
| WO2010131145A1 (en) | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| EP2582698B1 (en) | 2010-06-16 | 2016-09-14 | Vitae Pharmaceuticals, Inc. | Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use |
| MX2013009575A (es) | 2011-02-18 | 2014-10-14 | Exonhit Therapeutics Sa | Derivados de 6, 7-dialcoxi-3-isoquinolinol sustituidos como inhibidores de fosfodiesterasa 10 (pdei0a). |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| HUP1100241A3 (en) | 2011-05-06 | 2013-12-30 | Richter Gedeon Nyrt | Oxetane substituted pyrimidones |
| MX354965B (es) | 2012-04-02 | 2018-03-27 | Cytokinetics Inc | Metodo para mejorar la funcion del diafragma. |
| CN104395458A (zh) | 2012-04-11 | 2015-03-04 | 赛特凯恩蒂克公司 | 改善对骨骼肌疲劳的抵抗力 |
| AR091699A1 (es) | 2012-07-10 | 2015-02-25 | Astellas Pharma Inc | Derivado de indol carboxamida |
| DK3137622T3 (da) | 2014-04-29 | 2022-02-07 | Cytokinetics Inc | Fremgangsmåder til at reducere tilbagegang af vitalkapacitet |
| BR112017004505A2 (pt) | 2014-09-09 | 2018-01-23 | Astellas Pharma Inc. | agente terapêutico e método para prevenção e/ou tratamento de incontinência urinária, e, composto ou um sal do mesmo. |
| KR20180120701A (ko) | 2016-02-12 | 2018-11-06 | 아스테라스 세이야쿠 가부시키가이샤 | 테트라히드로이소퀴놀린 유도체 |
-
2017
- 2017-02-10 KR KR1020187026486A patent/KR20180120701A/ko not_active Withdrawn
- 2017-02-10 MX MX2018009759A patent/MX379159B/es unknown
- 2017-02-10 AU AU2017217663A patent/AU2017217663B2/en not_active Ceased
- 2017-02-10 CA CA3012839A patent/CA3012839A1/en active Pending
- 2017-02-10 US US15/429,738 patent/US9914741B2/en active Active
- 2017-02-10 PH PH1/2018/501694A patent/PH12018501694B1/en unknown
- 2017-02-10 DK DK17750801.7T patent/DK3413892T3/da active
- 2017-02-10 CN CN201780010949.1A patent/CN109069498B/zh active Active
- 2017-02-10 RU RU2018130002A patent/RU2743424C2/ru active
- 2017-02-10 SG SG11201806416XA patent/SG11201806416XA/en unknown
- 2017-02-10 PL PL17750801T patent/PL3413892T3/pl unknown
- 2017-02-10 LT LTEPPCT/US2017/017295T patent/LT3413892T/lt unknown
- 2017-02-10 MD MDE20181214T patent/MD3413892T2/ro unknown
- 2017-02-10 AR ARP170100336A patent/AR107592A1/es unknown
- 2017-02-10 HU HUE17750801A patent/HUE058820T2/hu unknown
- 2017-02-10 MA MA44018A patent/MA44018B1/fr unknown
- 2017-02-10 HR HRP20220655TT patent/HRP20220655T1/hr unknown
- 2017-02-10 JP JP2018541693A patent/JP6832943B2/ja not_active Expired - Fee Related
- 2017-02-10 WO PCT/US2017/017295 patent/WO2017139526A1/en not_active Ceased
- 2017-02-10 NZ NZ746311A patent/NZ746311A/en not_active IP Right Cessation
- 2017-02-10 TW TW106104493A patent/TWI719138B/zh not_active IP Right Cessation
- 2017-02-10 SI SI201731142T patent/SI3413892T1/sl unknown
- 2017-02-10 PT PT177508017T patent/PT3413892T/pt unknown
- 2017-02-10 ES ES17750801T patent/ES2913423T3/es active Active
- 2017-02-10 EP EP17750801.7A patent/EP3413892B1/en active Active
- 2017-02-10 CN CN202110837700.6A patent/CN113666938A/zh active Pending
- 2017-02-10 BR BR112018016475-5A patent/BR112018016475A2/en active Search and Examination
- 2017-02-10 EP EP22160176.8A patent/EP4032877A1/en not_active Withdrawn
- 2017-02-10 SM SM20220201T patent/SMT202200201T1/it unknown
- 2017-02-10 UA UAA201809258A patent/UA124879C2/uk unknown
- 2017-02-10 TW TW110103986A patent/TWI773118B/zh not_active IP Right Cessation
- 2017-02-10 RS RS20220483A patent/RS63240B1/sr unknown
-
2018
- 2018-01-17 US US15/873,571 patent/US10259821B2/en active Active
- 2018-07-23 ZA ZA2018/04947A patent/ZA201804947B/en unknown
- 2018-07-30 CO CONC2018/0007920A patent/CO2018007920A2/es unknown
- 2018-08-08 IL IL261055A patent/IL261055B/en active IP Right Grant
- 2018-08-10 CL CL2018002287A patent/CL2018002287A1/es unknown
-
2019
- 2019-03-04 US US16/291,481 patent/US10689393B2/en active Active
-
2020
- 2020-05-11 US US16/871,532 patent/US11479561B2/en active Active
-
2021
- 2021-02-01 JP JP2021014223A patent/JP7137650B2/ja active Active
-
2022
- 2022-06-03 CY CY20221100392T patent/CY1125222T1/el unknown
- 2022-09-13 US US17/944,060 patent/US20230125280A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018002287A1 (es) | Derivados de tetrahidroisoquinolina. | |
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| MX2020003415A (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso. | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| TN2020000001A1 (en) | Carboxamides as modulators of sodium channels | |
| MX2018012486A (es) | Composiciones para aplicacion topica de compuestos. | |
| MX2017007489A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
| MX2019010757A (es) | Métodos y composiciones relacionados con el tratamiento combinado con antiinflamatorios y nanoportadores sintéticos que comprenden un inmunosupresor. | |
| CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
| CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
| CR20140365A (es) | Compuestos de carbamato y preparación y uso de los mismos | |
| BR112017015310A2 (pt) | uso de pgr4 como um agente anti-inflamatório | |
| PL417066A1 (pl) | Inhibitory arginazy oraz ich zastosowania terapeutyczne | |
| MX2017013141A (es) | Composicion farmaceutica para la prevencion y/o tratamiento de dermatitis atopica que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. | |
| UY36761A (es) | Formulación oral sólida que contiene irinotecán y método 20 de preparación de la misma | |
| CO2019000941A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
| MX2015009269A (es) | Composiciones farmaceuticas que comprenden donadores de nitroxilo. | |
| EA201691808A1 (ru) | Кортикостероидные композиции для местного применения | |
| WO2019090347A8 (en) | Adenosine pathway inhibitors for cancer treatment | |
| CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
| MX393613B (es) | Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas. | |
| CL2015000039A1 (es) | Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis. | |
| MX392182B (es) | Combinaciones de dosis fija y formulaciones que comprenden ácido 8-hidroxi-2,2,14,14 tetrametilpentadecanodioico (etc1002) y ezetimiba y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| JOP20190053A1 (ar) | مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط |